ConductScience.org, home

Paper42336655

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.

Roulleaux-Dugage M and 17 others. J Immunother Cancer, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC. Papers, record 42336655. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42336655

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.
PubMed
Journal
J Immunother Cancer
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Roulleaux-Dugage MMatthieuhttps://orcid.org/0000-0003-3192-2342
2Yurchenko AAndrey
3Nikolaev SSergey
4Nabet BBarzinhttps://orcid.org/0000-0002-4824-3533
5Corgnac SStéphaniehttps://orcid.org/0000-0002-3014-9178
6Anquetil CCéline
7Srivastava MKMinu K
8Gayevskiy VVelimir
9McNally VVirginia
10Mezquita LLaurahttps://orcid.org/0000-0003-0936-7338
11Perfettini JLJean-Luc
12Mouraud SSeverine
13Massard CChristophe
14Besse BBenjamin
15Loriot YYohann
16Marabelle AAurelienhttps://orcid.org/0000-0002-5816-3019
17Chaput NNathalie
18Auclin EEdouard

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lung NeoplasmsMajor topic
Liver NeoplasmsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Vascular Endothelial Growth Factor AMajor topic
ImmunotherapyMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Humans
Female
Male
Bevacizumab
Tumor Microenvironment
Aged
Middle Aged
Drug Resistance, Neoplasm

Source PubMed

Download CSV of topics

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129324807VEGF may contribute to macrophage recruitment and M2 polarization in the decidua.PLoS One2018https://conductscience.org/library/papers/29324807PubMed
234614508A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes.Blood Adv2021https://conductscience.org/library/papers/34614508PubMed
338600370Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials.Nat Rev Clin Oncol2024https://conductscience.org/library/papers/38600370PubMed
438438735Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.Nat Med2024https://conductscience.org/library/papers/38438735PubMed
531122901
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol2019https://conductscience.org/library/papers/31122901PubMed
635090594Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.Cancer Cell2022https://conductscience.org/library/papers/35090594PubMed
730456891Autocrine VEGF signalling on M2 macrophages regulates PD-L1 expression for immunomodulation of T cells.J Cell Mol Med2019https://conductscience.org/library/papers/30456891PubMed
833008914Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.Sci Immunol2020https://conductscience.org/library/papers/33008914PubMed
929508855Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/29508855PubMed
1029863955Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.N Engl J Med2018https://conductscience.org/library/papers/29863955PubMed
1136368318High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer.Cancer Cell2022https://conductscience.org/library/papers/36368318PubMed
1234626838IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.J Thorac Oncol2022https://conductscience.org/library/papers/34626838PubMed
1338207030Deterministic reprogramming of neutrophils within tumors.Science2024https://conductscience.org/library/papers/38207030PubMed
1433476593First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.Lancet Oncol2021https://conductscience.org/library/papers/33476593PubMed
1536862804Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer.Cancer Discov2023https://conductscience.org/library/papers/36862804PubMed
1629327044Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.JAMA Oncol2018https://conductscience.org/library/papers/29327044PubMed
1741825453Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.Lancet Oncol2026https://conductscience.org/library/papers/41825453PubMed
1832997907Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.N Engl J Med2020https://conductscience.org/library/papers/32997907PubMed
1928411193Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.Cancer Immunol Res2017https://conductscience.org/library/papers/28411193PubMed
2027718847Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.N Engl J Med2016https://conductscience.org/library/papers/27718847PubMed

See all 31 referencesDownload CSV of references

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
FLT12321PubTator's text mininghttps://conductscience.org/library/genes/2321NCBI Gene
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42336655

GET https://conductscience.org/api/papers/v1/42336655/references?page=2